Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 68071-3150

4 FDA label images from Nucare Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 68071-3150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3150 3

68071 3150 3
Packaging label for Cyclobenzaprine Hydrochloride 10 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets, each containing 10 mg Cyclobenzaprine Hydrochloride. The round yellow tablets are debossed with '1G' on one side and '283' on the other side. The label includes storage instructions and a clear warning to keep out of reach of children.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Chemical structure of Cyclobenzaprine Hydrochloride, showing the molecular arrangement with a tricyclic core and attached amine and hydrochloride components.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
A data table showing the percentage incidence of adverse events among participants receiving Cyclobenzaprine HCl Tablets 5 mg, Cyclobenzaprine HCl Tablets 10 mg, and Placebo. The events include drowsiness, dry mouth, fatigue, and headache, with corresponding percentages for each group and sample sizes noted.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
A table comparing adverse event rates of drowsiness, dry mouth, and dizziness in clinical studies versus a surveillance program for Cyclobenzaprine Hydrochloride Tablets, 10 mg. The data shows percentages reported for each side effect in both study types.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.